Immunodeficient mice and humanized liver mice

CAS number:

Molecular formula:

molecular weight:

Chemical structure:

The cooperative factory of Arshine Group has the fourth generation of humanized liver mice with completely independent intellectual property rights, breaking the long-term blockade of technology and sales to the United States and Japan.

The factory has obtained the license for experimental animal use and the production of experimental animals, and has established a clean animal laboratory with an area of over 1000 Square meter that is fully GMP-compliant. It produces 200,000 mice with multiple immunodeficiency mice and humanized liver.

SNI mice (Knock out the TALEN gene), have completed the humanization model of xenograft (PDX) derived from lung cancer, leukemia, liver cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer and other cancer patients; and published 20 high-level SCI papers with an impact factor of over 100. There are 7 pre-clinical evaluation drugs, and currently 3 drugs have obtained clinical trial approval through clinical approval.


NSIN mice (Knock out Fah at NSI), no fur, transplanted tumors are easier to observe and measure, and compared with other similar immunodeficient mice, less cell dose is required for modeling, tumor formation is better, living body imaging is reduced, and tumors are detected more quickly and accurately. .


NSIF mice (Knock out Foxn1 at NSI), This line of mice controls NTBC uptake to induce hepatocyte injury in mice, and is highly efficient for human normal liver tissue transplantation. The humanized liver mouse model established by NSIF mice can mimic the metabolism of drugs in humans. , the metabolism and toxicity test of the drug.